Hereditary hemorrhagic telangiectasia (HHT) can be fatal. However, it does not affect the average life expectancy of most people. Complications can occur when blood vessels rupture in vital organs.
A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
In the April 2010 supplement to this journal, a series of articles prepared by the Center for Public Genomics at Duke University analyzed how patenting and licensing affect access to clinical genetic ...
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for hereditary haemorrhagic telangiectasia (HHT), the second most common inherited ...
Medical imaging, like MRI, CT, and ultrasound, plays a vital role in diagnosing HHT, formerly known as Osler-Weber-Rendu syndrome. Imaging can help guide treatment and improve your outlook with HHT.
Most people with this condition live a full, typical life, but it can be life threatening if a blood vessel ruptures in an internal organ and bleeds uncontrollably. Osler-Weber-Rendu syndrome, which ...
A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results